Haloperidol Depo Krka

Haloperidol Depo Krka is a long‑acting injectable formulation containing the antipsychotic haloperidol, a butyrophenone derivative. Marketed in the European Union and prescribed by healthcare professionals, it is administered by intramuscular injection to provide sustained plasma levels. The product is classified as a Schedule IV prescription drug and is indicated for the management of certain psychotic disorders. Its mechanism involves dopamine D2 receptor antagonism in adult patients.

Haloperidol Depo Krka is used in clinical practice for several psychiatric conditions where sustained antipsychotic coverage is desired.

- Maintenance treatment of schizophrenia in patients who have responded to oral haloperidol. - Management of acute psychotic episodes when rapid stabilization is required. - Adjunctive therapy for manic episodes associated with bipolar disorder. - Prevention of relapse in chronic psychotic disorders after initial stabilization. - Use in patients who have difficulty adhering to daily oral medication regimens.

The safety profile of Haloperidol Depo Krka includes a range of adverse effects that may be observed during therapy, varying from mild, transient symptoms to rare but potentially serious conditions.

Common: - Drowsiness or sedation. - Extrapyramidal symptoms such as tremor, rigidity, or akathisia. - Dry mouth and constipation. - Blurred vision or dizziness. - Weight gain or increased appetite. - Nausea or vomiting.

Serious: - Neuroleptic malignant syndrome, a rare but life‑threatening reaction. - Tardive dyskinesia, characterized by involuntary movements. - Significant cardiac arrhythmias, including QT prolongation. - Severe hypotension or syncope. - Hepatic dysfunction or elevated liver enzymes.

Patients should promptly inform their healthcare provider if any serious or persistent side effects occur.

When prescribing Haloperidol Depo Krka, clinicians consider several precautions to ensure safe use and to minimize risk.

- Assess cardiovascular status, especially for patients with a history of arrhythmias or prolonged QT interval. - Evaluate for prior extrapyramidal reactions or movement disorders before initiating therapy. - Use caution in patients with hepatic or renal impairment, adjusting monitoring as needed. - Discuss potential risks with pregnant or breastfeeding women; the drug is classified as pregnancy category C. - Monitor for signs of neuroleptic malignant syndrome, especially during the first weeks of treatment.

Haloperidol Depo Krka may interact with other medications, affecting its efficacy or safety profile.

Avoid: - Concomitant use with other potent dopamine antagonists or high‑potency antipsychotics, which can increase the risk of extrapyramidal symptoms. - Co‑administration with drugs that markedly prolong the QT interval, such as certain antiarrhythmics or macrolide antibiotics.

Use with caution: - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) that can raise haloperidol plasma concentrations. - CYP3A4 inducers (e.g., carbamazepine, rifampin) that may reduce therapeutic levels. - CNS depressants, including benzodiazepines or alcohol, which can enhance sedation. - Anticholinergic agents, which may mask early signs of extrapyramidal side effects.